Domača stran22UA • FRA
add
BioNTech
Prejšnji trg. dan.
119,00 €
Dnevni razpon
114,10 € - 120,00 €
Letni razpon
69,70 € - 124,60 €
Tržna kapitalizacija
29,05 mrd. USD
Povprečni obseg
1,19 tis.
Razm. P/E
-
Dividendna donosnost
-
Primarna borza
NASDAQ
V novicah
Finančni podatki
Izkaz poslovnega izida
Prihodek
Čisti dohodek
| (EUR) | sep. 2024info | Sprememba L/L |
|---|---|---|
Prihodek | 1,24 mrd. | 39,04 % |
Stroški poslovanja | 1,04 mrd. | 53,43 % |
Čisti dohodek | 198,10 mio. | 23,35 % |
Čista dobičkovnost prihodkov | 15,91 | −11,32 % |
Earnings per share | 0,81 | 20,90 % |
EBITDA | 65,30 mio. | −30,31 % |
Efektivna davčna stopnja | −24,83 % | — |
Bilanca stanja
Skupna sredstva
Skupne obveznosti
| (EUR) | sep. 2024info | Sprememba L/L |
|---|---|---|
Denar. in kratkor. naložbe | 16,71 mrd. | 6,10 % |
Skupna sredstva | 22,40 mrd. | 0,87 % |
Skupne obveznosti | 3,29 mrd. | 40,43 % |
Celoten lastniški kapital | 19,11 mrd. | — |
Shares outstanding | 239,74 mio. | — |
Razmerje P/B | 1,49 | — |
Donosnost sredstev | 0,23 % | — |
Donosnost kapitala | 0,27 % | — |
Denarni tok
Neto sprememba denarnih sredstev
| (EUR) | sep. 2024info | Sprememba L/L |
|---|---|---|
Čisti dohodek | 198,10 mio. | 23,35 % |
Denar iz dejavnosti | −638,90 mio. | −178,76 % |
Denar iz naložb | −142,10 mio. | 88,47 % |
Denar iz financiranja | −7,90 mio. | 97,46 % |
Neto sprememba denarnih sredstev | −752,10 mio. | −12,12 % |
Prost denarni tok | −684,45 mio. | −217,91 % |
Vizitka
BioNTech SE is a global biotechnology company headquartered in Mainz that develops immunotherapies and vaccines, particularly for cancer and infectious diseases.
The company utilizes technology platforms including mRNA-based therapies, targeted therapies, and immunomodulators, to develop its treatments. BioNTech's pipeline includes several late-stage programs in oncology testing combination therapy approaches to improve treatment outcomes.
In the field of infectious diseases, BioNTech, partnering with Pfizer, developed Comirnaty, the first approved mRNA-based vaccine, which was widely used during the COVID-19 pandemic. Wikipedia
Generalni direktor
Datum ustanovitve
2008
Spletno mesto
Zaposleni
6.133
